Vaccitech plc (NASDAQ:VACC – Get Rating) – Research analysts at HC Wainwright boosted their FY2022 EPS estimates for Vaccitech in a note issued to investors on Monday, November 14th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of $0.26 for the year, up from their previous forecast of ($0.36). HC Wainwright currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Vaccitech’s current full-year earnings is ($0.04) per share. HC Wainwright also issued estimates for Vaccitech’s Q4 2022 earnings at ($0.43) EPS, Q1 2023 earnings at ($0.50) EPS, Q2 2023 earnings at ($0.53) EPS, Q3 2023 earnings at ($0.56) EPS, Q4 2023 earnings at ($0.56) EPS and FY2023 earnings at ($2.14) EPS.
Separately, Morgan Stanley lowered their target price on Vaccitech from $19.00 to $16.00 and set an “overweight” rating on the stock in a research note on Monday, August 15th.
Vaccitech Stock Performance
Institutional Trading of Vaccitech
A hedge fund recently bought a new position in Vaccitech stock. Alphabet Inc. purchased a new position in Vaccitech plc (NASDAQ:VACC – Get Rating) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 1,513,644 shares of the company’s stock, valued at approximately $4,844,000. Alphabet Inc. owned approximately 4.06% of Vaccitech as of its most recent filing with the Securities and Exchange Commission. 12.86% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling
In other Vaccitech news, insider Graham Griffiths sold 10,000 shares of Vaccitech stock in a transaction on Thursday, August 25th. The shares were sold at an average price of $7.39, for a total value of $73,900.00. Following the completion of the transaction, the insider now owns 104,209 shares of the company’s stock, valued at $770,104.51. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 7.00% of the stock is currently owned by insiders.
Vaccitech Company Profile
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer.
- Get a free copy of the StockNews.com research report on Vaccitech (VACC)
- Use The Airbnb Stock Implosion to Your Advantage
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- International Game Technology is Well Worth the Gamble
- Why Lowe’s Is Up And Home Depot Down
- The TJX Companies Could Break Out To New Highs
Receive News & Ratings for Vaccitech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccitech and related companies with MarketBeat.com's FREE daily email newsletter.